BetterLife Pharma (BETRF) Income from Continuing Operations (2015 - 2022)
BetterLife Pharma (BETRF) posted quarterly Income from Continuing Operations of 2357940.88 for Q2 2022, down 25.8% year-over-year from 3177903.84 in Q2 2021, and up 23.11% quarter-over-quarter from 3066588.09 in Q1 2022.
BetterLife Pharma (BETRF) Income from Continuing Operations (2015 - 2022) Analysis & Trends
BetterLife Pharma's Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 2357940.88 for Q2 2022.
- In Q2 2022, Income from Continuing Operations fell 25.8% year-over-year to 2357940.88; the TTM figure through Apr 2022 stood at 10087082.24 (up 66.27% YoY), while the FY2026 annual figure was 1086493.73, up 56.56% from the prior year.
- Income from Continuing Operations for Q2 2022 stood at 2357940.88, up from 3066588.09 in the prior quarter.
- The five-year high for Income from Continuing Operations was 463395.5 in Q1 2018, with the low at 21229736.3 in Q1 2021.
- The 5-year median for Income from Continuing Operations is 1991918.18 (2018), against an average of 3388179.84.
- The sharpest annual moves came in 2018 and 2021: Income from Continuing Operations jumped 155.82% in 2018, then tumbled 20655.48% in 2021.
- BetterLife Pharma's Income from Continuing Operations stood at 1546661.0 in 2018, then sank by 34.76% to 2084225.35 in 2019, then tumbled by 170.89% to 5645968.58 in 2020, then soared by 68.96% to 1752575.32 in 2021, then tumbled by 34.54% to 2357940.88 in 2022.
- Business Quant data shows BETRF's Income from Continuing Operations at 2357940.88 in Q2 2022, 3066588.09 in Q1 2022, and 1752575.32 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | BetterLife Pharma | 36.45 Mn | 36.42 Mn | - | -418,546.79 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2022 | -2.36 Mn |
| Jan 31, 2022 | -3.07 Mn |
| Oct 31, 2021 | -1.75 Mn |
| Jul 31, 2021 | -2.91 Mn |
| Apr 30, 2021 | -1.87 Mn |
| Jan 31, 2021 | -21.23 Mn |
| Oct 31, 2020 | -5.65 Mn |
| Jul 31, 2020 | -1.15 Mn |
| Apr 30, 2020 | -9,030.52 |
| Apr 30, 2019 | -2.08 Mn |
| Oct 31, 2018 | -1.55 Mn |
| Jul 31, 2018 | -1.90 Mn |
| Apr 30, 2018 | -2.37 Mn |
| Jan 31, 2018 | 463,395.50 |
| Jul 31, 2017 | -257,120.00 |
| Apr 30, 2017 | -294,307.00 |
| Jan 31, 2017 | -830,187.00 |
| Oct 31, 2016 | -693,916.00 |
| Jul 31, 2016 | -1.18 Mn |
| Apr 30, 2016 | -3.33 Mn |